ArticleOdontology2026
Association of ALKBH1 overexpression with metastasis, prognosis, and immunotherapy response in head and neck squamous cell carcinoma.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) is an aggressive form of cancer with high metastasis rates and poor prognosis. Therefore, identifying potential biomarkers to improve prognosis and develop effective treatment is essential. ALKBH1, a member of the AlkB family of dioxygenases, has recently arisen as a potential biomarker in several types of cancer; however, its role in HNSCC still remains unclear. In this study, we significantly analyzed ALKBH1 expression and its clinicopathological correlation, immune infiltration, and immune gene regulations from the Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma (TCGA-HNSC) dataset. The prognosis was evaluated by the Kaplan-Meier plotter. We further confirmed ALKBH1 mRNA and protein expression levels by quantitative reverse-transcriptase PCR (qRT-PCR) and western blot. ALKBH1 was also assessed for its predictive value for treatment response in metastatic HNSCC using immunotherapy datasets. The results showed that ALKBH1 expression was significantly increased in HNSCC patients and correlated with advanced clinicopathological features, immune cell infiltration, and poor overall survival. Functional enrichment analysis identified pathways regulating cancer development and metastasis that are modulated by ALKBH1. Therefore, ALKBH1 can be considered a new biomarker for predicting metastasis and poor prognosis in HNSCC, suggesting that it may serve as a potential therapeutic target.
Indexed as
Identifiers
41483323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.